Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05253352 · ClinicalTrials.gov registry record
Mapping and Quantifying Lymphatic Drainage of the Arm's Alternate Pathway
A clinical trial of Lymphatic System, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 142
- Enrollment target
- 1
- Study location
NCT05253352: Recruiting study of Lymphatic System, sponsored by Beth Israel Deaconess Medical Center.
NCT05253352 is a study of Lymphatic System that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 142 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05253352, a study of Lymphatic System, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
Using indocyanine green (ICG) lymphography and lymphoscintigraphy with SPECT/CT imaging, the aim is to evaluate the anatomy of the lymphatic system pathway in two separate populations: healthy female volunteers and women with a history of breast cancer who did not develop lymphedema.
Primary Outcome
Indocyanine green (ICG) lymphography of bilateral upper arms
Conditions Studied
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2026-12 |
What NCT05253352 shows while recruiting
NCT05253352 is an observational study that tracks outcomes without assigning an intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Lymphatic System appearing as the primary indexed condition, and to 0 interventions.
NCT05253352 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05253352 about?
NCT05253352 is a clinical study titled "Mapping and Quantifying Lymphatic Drainage of the Arm's Alternate Pathway". Using indocyanine green (ICG) lymphography and lymphoscintigraphy with SPECT/CT imaging, the aim is to evaluate the anatomy of the lymphatic system pathway in two separate populations: healthy female volunteers and women with a history of breast cancer who did not develop lymphedema.
What is the current status of trial NCT05253352?
This trial is currently recruiting. The enrollment target is 142 participants. The study started on 2022-04-01. Estimated completion is 2026-12.
What conditions does trial NCT05253352 study?
This clinical trial studies the following conditions: Lymphatic System.
Who is sponsoring clinical trial NCT05253352?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05253352 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI